The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AERIE PHARMACEUTICALS INC | COM | 00771V108 | 13,152 | 419,652 | SH | SOLE | 419,652 | 0 | 0 | ||
AKEBIA THERAPEUTICS INC | COM | 00972D105 | 16,847 | 1,516,387 | SH | SOLE | 1,516,387 | 0 | 0 | ||
ALDER BIOPHARMACEUTICALS INC | COM | 014339105 | 92,386 | 3,201,183 | SH | SOLE | 3,201,183 | 0 | 0 | ||
FLEXION THERAPEUTICS INC | COM | 33938J106 | 51,416 | 2,283,131 | SH | SOLE | 2,283,131 | 0 | 0 | ||
INOGEN INC | COM | 45780L104 | 113,543 | 3,549,320 | SH | SOLE | 3,549,320 | 0 | 0 | ||
INTERSECT ENT INC | COM | 46071F103 | 0 | 0 | SH | SOLE | 0 | 0 | 0 | ||
NEVRO CORP | COM | 64157F103 | 105,199 | 2,194,841 | SH | SOLE | 2,194,841 | 0 | 0 | ||
OPHTHOTECH CORP | COM | 683745103 | 228,485 | 4,910,487 | SH | SOLE | 5,901,819 | 0 | 0 | ||
OTONOMY INC | COM | 68906L105 | 76,909 | 2,175,025 | SH | SOLE | 2,175,025 | 0 | 0 | ||
TETRAPHASE PHARMACEUTICALS INC | COM | 88165N105 | 8,479 | 231,419 | SH | SOLE | 1,475,000 | 0 | 0 | ||
TOKAI PHARMACEUTICALS INC | COM | 88907J107 | 13,381 | 1,184,196 | SH | SOLE | 1,178,992 | 0 | 0 | ||
VANGUARD INDEX FDS | TOTAL STK MKT | 922908769 | 319,508 | 2,979,100 | SH | SOLE | 2,979,100 | 0 | 0 | ||
VANGUARD INTL EQUITY INDEX F | FTSE EUROPE ETF | 922042874 | 113,916 | 2,101,000 | SH | SOLE | 2,101,000 | 0 | 0 | ||
WRIGHT MED GROUP INC | RIGHT 03/01/2019 | 98235T115 | 20,296 | 4,720,065 | PRN | SOLE | 0 | 0 | 4,720,065 | ||
XENON PHARMACEUTICALS INC | COM | 98420N105 | 2,151 | 127,563 | SH | SOLE | 127,563 | 0 | 0 |